ClinicalTrials.gg
CompletedNCT07176832STILIQUpdated Sep 16, 2025

Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)

A Phase 1 interventional study of Stiripentol capsule (Diacomit®) and Stiripentol oral suspension (Diacomit®) in Dravet Syndrome, Epilepsy and Childhood, sponsored by Biocodex. Completed at 2 sites in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Biocodex · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Epilepsies, Myoclonic with a site in France — 4 open to participants now, 8 under way, 3 of them phase 3. Epilepsies, Myoclonic · France.

Enrollment
13th of 13
24 · median 144
Started
2025
with 4 others
Phase 1
Only one
of the 18
Registered
18th of 18
by date
Lead sponsor
1 of 18
Biocodex

Among the 18 studies in Epilepsies, Myoclonic with a site in France, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 1, and was the 18th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

4 of the 18 studies in Epilepsies, Myoclonic with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Epilepsies, Myoclonic with a site in France, or all of them as a file.
02

Study summary

This is a Phase I, open-label, randomized, single-center, two-way cross-over study evaluating the relative bioavailability, pharmacokinetics, safety, and palatability of two formulations of stiripentol (Diacomit®), indicated in Dravet syndrome. The investigational products are 500 mg capsules (reference) and a 50 mg/mL oral suspension (test).

The primary objective is to compare the relative bioavailability of the two formulations after a single 1,000 mg oral dose under fed conditions, based on Cmax, AUC0-t, and AUC0-∞. Secondary objectives include other PK parameters (tmax, tlag, ke, t1/2) and characterization of metabolites MIa and MIb. Palatability of the suspension will be assessed by questionnaire.

Safety evaluation will include adverse events, laboratory tests, ECGs, urinalysis, drug and alcohol screening, serology, and vital signs.

Twenty-four healthy volunteers (18-50 years) will be enrolled. Eligibility: BMI 18-30 kg/m², weight ≥50 kg, normal ECG and labs, and informed consent. Women of childbearing potential must use effective contraception and test negative for pregnancy. Exclusions: significant disease, recent surgery or blood donation, hypersensitivity, difficulty swallowing, use of CYP modulators (e.g., carbamazepine, grapefruit, herbal products), drug or alcohol abuse, smoking >5 cigarettes/day, or inability to follow dietary restrictions. Subjects testing positive for HIV, HBV, HCV, or drugs of abuse will also be excluded.

Each participant will attend a screening visit within 28 days before dosing, then two 3-day hospitalizations separated by a 7-15-day washout. On Day 1 of each period, they will receive either two capsules (1,000 mg) or 20 mL suspension (1,000 mg). Blood will be collected at 36 timepoints (≈180 mL total) for PK assessment.

The total study duration per subject is about seven weeks, including screening, hospitalization, dosing, washout, and follow-up. Treatment consists of one dosing day per period.

Sample size was based on prior data: 21 pairs provide 80% power for bioequivalence within 0.80-1.25 bounds; 24 subjects will be recruited to account for dropouts. Analyses will include the Safety Set, PK Concentrations Set, and PK Analysis Set.

This trial aims to establish whether the oral suspension provides a PK profile comparable to capsules, while generating safety, tolerability, and palatability data to support a more convenient formulation for Dravet syndrome patients.

Read the detailed description

Stiripentol (Diacomit®) is currently marketed in two dosage forms: capsules (250 and 500 mg) and powder for oral suspension in sachets (250 and 500 mg). The powder formulation was developed for patients unable to swallow capsules. A previous study in healthy volunteers demonstrated that the capsule and sachet formulations were bioequivalent in terms of AUC but not Cmax. The Cmax of the sachet formulation was approximately 23% higher than that of the capsule, outside the accepted bioequivalence range. As a result, clinical supervision is recommended when switching between capsule and sachet formulations.

According to the European Summary of Product Characteristics (SmPC), stiripentol dosage escalation should be gradual, starting at 20 mg/kg/day and increasing stepwise depending on age. Dravet syndrome typically begins in infancy, and early initiation of antiepileptic treatment is recommended. A new oral suspension formulation (50 mg/mL) has been developed to facilitate flexible dose adjustments and accurate administration in pediatric patients, especially infants, where precise titration is essential.

This clinical study aims to compare the relative bioavailability of the new oral suspension (test formulation) to the capsule (reference formulation) after a single 1,000 mg dose under fed conditions. In addition to pharmacokinetic endpoints, safety, tolerability, and palatability will be assessed in healthy volunteers. The results will provide critical information on whether the new suspension offers a pharmacokinetic profile comparable to the capsule while improving dosing flexibility and patient convenience in clinical practice.

03

Conditions studied

  • Dravet Syndrome
  • Epilepsy
  • Childhood
  • Epileptic Encephalopathy
  • Pediatric Epilepsy

Keywords

  • Stiripentol
  • Diacomit
  • Oral Suspension
  • Bioavailability
  • Pharmacokinetics
  • Antiepileptic Drug
  • Crossover Study
  • Healthy Volunteers
  • Pediatric Epilepsy
  • Dravet Syndrome Treatment
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 50 years (inclusive).
  • Considered healthy after a comprehensive clinical assessment (medical history + complete physical exam).
  • (BMI) between 18 and 30 kg/m² (inclusive) and body weight ≥ 50 kg at screening.
  • Normal blood pressure (BP) and heart rate (HR) after 10 minutes supine at screening : Systolic BP: 90-145 mmHg, Diastolic BP: 45-90 mmHg, HR: 40-90 bpm, Or values outside these ranges but judged not (NCS) by the Investigator.
  • Normal at screening (10-min resting 12-lead ECG): PR interval: 110-210 ms, QRS interval : \< 120 ms, interval: ≤ 450 ms, No evidence of sinus node dysfunction, Or values outside these ranges but judged NCS by the Investigator.
  • Laboratory parameters within normal ranges (hematology, biochemistry, urinalysis); slight deviations allowed if not clinically relevant per Investigator.
  • Women of non-, or women of childbearing potential using at least one acceptable method throughout the study and 1 month after last treatment.
  • Female subjects of childbearing potential: negative pregnancy test (serum or urine) at screening and Day 0.
  • Covered by Health Insurance System and/or compliant with National Law requirements for biomedical research.
  • Able and willing to comply with study requirements.
  • Written obtained.

Exclusion criteria

Exclusion Criteria

  • Unsuitable veins for repeated venipuncture.
  • Relevant history/presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, psychiatric, systemic, or infectious disease.
  • Evidence of any acute or chronic disease.
  • History of suicidal ideation or suicide attempt.
  • Surgery (including clinical trial procedures) within 2 months before dosing.
  • Blood donation within 2 months before dosing.
  • History/presence of drug , asthma, or allergy.
  • Known hypersensitivity to study materials or related compounds.
  • Inability/difficulty swallowing capsules.
  • No possibility of emergency contact.
  • Any drug intake (except paracetamol) within 4 weeks prior to dosing or \< 5 half-lives (whichever longer). Prohibited: carbamazepine, phenytoin, phenobarbital, CYP enzyme modulators.
  • Use of herbal products affecting CYP enzymes within 2 weeks or \< 5 half-lives before dosing.
  • Special diets (vegetarian, vegan, gluten-free).
  • Vigorous exercise from 4 days before dosing until post-study assessments.
  • Pregnant or breastfeeding women.
  • Drug/alcohol abuse history, daily alcohol intake > 4 drinks, or positive alcohol test.
  • Excessive xanthine beverages (> 5 cups/day).
  • Nicotine use > 5 cigarettes/day or inability to abstain 48h before and during study.
  • Intake of grapefruit/Seville oranges/poppy seed or other CYP modulators 1 week before dosing and during study.
  • Intake of methylxanthines (coffee, tea, cola, cocoa, mate, guarana, chocolate) or quinine (e.g., tonic water) from 48h before dosing and during study.
  • Unable/unwilling to follow diet requirements (see protocol section 10.7).
  • Positive test for , antibody, or 1/2.
  • Positive drug screen.
  • Significant biological or clinical abnormalities judged incompatible with study.
  • Participation in another interventional trial during exclusion period or product within last 60 days or \< 5 half-lives.
  • Under guardianship, curatorship, or deprived of liberty.
  • Under Court protection.
  • Would exceed €6000 compensation for biomedical research in last 12 months (including this study).
  • Health status not allowing provision of .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence A : Stiripentol Capsule then Oral Suspension

    Subjects randomized to Sequence A will receive a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) in Period 2 after a 7-15 day

    Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)

  • Experimental
    Sequence B : Stiripentol Oral Suspension then Capsule

    Subjects randomized to Sequence B will receive a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) in Period 2 after a 7-15 day washout.

    Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)

Interventions

  • Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.

    Also known as: Stiripentol 500 mg capsule, Diacomit® capsule

  • Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.

    Also known as: Stiripentol 50 mg/mL suspension, Diacomit® oral suspension

06

What researchers measure

Primary outcomes

  1. Relative bioavailability of stiripentol oral suspension (50 mg/mL) vs capsule (500 mg) after a single 1,000 mg oral dose with food, assessed by PK parameters Cmax, AUC0-t, and AUC0-∞ using plasma LC-MS.

    The relative bioavailability of stiripentol oral suspension (50 mg/mL) versus capsule (500 mg) after a single 1,000 mg oral dose under fed conditions. It will be assessed by calculating geometric mean ratios with 90% confidence intervals for the main pharmacokinetic parameters: maximum observed plasma concentration (Cmax), area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t), and area under the concentration-time curve extrapolated to infinity (AUC0-∞). Plasma concentrations of stiripentol will be measured using validated liquid chromatography-mass spectrometry (LC-MS) methods to ensure accuracy and reliability of the pharmacokinetic evaluation.

    Time frame: Up to 36 hours post-dose (per period)

Secondary outcomes

  1. Other PK parameters of stiripentol

    Time to maximum concentration (tmax)

    Time frame: Up to 36 hours post-dose (per period).

  2. Safety and tolerability of stiripentol

    Number, nature, incidence, seriousness, severity, and resolution of adverse events following single-dose administration.

    Time frame: From dosing to end of study (~7 weeks per participant).

  3. Palatability of stiripentol oral suspension

    Assessed using a self-administered palatability questionnaire completed 20 minutes after administration of the oral suspension

    Time frame: 20 minutes after administration of the oral suspension

  4. Other PK parameters of stiripentol

    Time before start of absorption (tlag)

    Time frame: Up to 36 hours post-dose (per period)

  5. Other PK parameters of stiripentol

    Elimination rate constant (ke)

    Time frame: Up to 36 hours post-dose (per period)

  6. Other PK parameters of stiripentol

    Terminal half-life (t1/2)

    Time frame: Up to 36 hours post-dose (per period)

  7. PK parameters of stiripentol metabolites (MIa, MIb)

    Maximum concentration (Cmax)

    Time frame: Up to 36 hours post-dose (per period)

  8. PK parameters of stiripentol metabolites (MIa, MIb)

    Area under the curve from time 0 (pre-dose) to the last measurable concentration (AUC0-t)

    Time frame: Up to 36 hours post-dose (per period)

  9. PK parameters of stiripentol metabolites (MIa, MIb)

    Area under the curve from time 0 (pre-dose) to infinity (AUC0-∞)

    Time frame: Up to 36 hours post-dose (per period)

  10. PK parameters of stiripentol metabolites (MIa, MIb)

    Time of occurrence of maximum concentration (tmax)

    Time frame: Up to 36 hours post-dose (per period)

  11. PK parameters of stiripentol metabolites (MIa, MIb)

    Elimination rate constant (ke)

    Time frame: Up to 36 hours post-dose (per period)

  12. PK parameters of stiripentol metabolites (MIa, MIb)

    Apparent terminal elimination half-life (t1/2) measured from plasma concentrations using Liquid chromatography-mass spectrometry (LC-MS)

    Time frame: Up to 36 hours post-dose (per period)

07

Study locations

2 sites
  • 3 Chemin d'Armancourt
    Compiègne, 60200, France
  • EUROFINS OPTIMED, 1 rue des Essarts
    Gières, 38610, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Aug 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 16, 2025
StartActual
Jun 1, 2025
Primary completionActual
Aug 27, 2025
CompletionActual
Aug 27, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07176832
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Jun 1, 2025
Primary completion
Aug 27, 2025
Completion
Aug 27, 2025
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stiripentol

Start the discussion